Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Receivables (2020 - 2025)

Historic Receivables for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $56.6 million.

  • Cytek Biosciences' Receivables rose 759.59% to $56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.6 million, marking a year-over-year increase of 759.59%. This contributed to the annual value of $60.6 million for FY2024, which is 833.21% up from last year.
  • Cytek Biosciences' Receivables amounted to $56.6 million in Q3 2025, which was up 759.59% from $56.2 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Receivables high stood at $60.6 million for Q4 2024, and its period low was $24.0 million during Q2 2021.
  • In the last 5 years, Cytek Biosciences' Receivables had a median value of $49.2 million in 2022 and averaged $45.6 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 7516.19% in 2021, then plummeted by 1003.75% in 2024.
  • Cytek Biosciences' Receivables (Quarter) stood at $29.8 million in 2021, then soared by 64.19% to $48.9 million in 2022, then grew by 14.46% to $55.9 million in 2023, then grew by 8.33% to $60.6 million in 2024, then decreased by 6.53% to $56.6 million in 2025.
  • Its Receivables stands at $56.6 million for Q3 2025, versus $56.2 million for Q2 2025 and $55.0 million for Q1 2025.